A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).

Marika Ciprotti,Niall C. Tebbutt,Fook-Thean Lee,Sze Ting Lee,Dave C. McKee,Graeme J. O’Keefe,Sylvia J. Gong,Geoffrey Chong,Hui K. Gan,Wendie Hopkins,Bridget Chappell,Fiona E. Scott,Martin W. Brechbiel,Archie N. Tse,Mendel Jansen,Manabu Matsumura,Rira Watanabe,Robert A. Beckman,Jonathan Greenberg,Andrew M. Scott

A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).

2013

2583 Background: Death receptor 5 (DR5) is a member of the TNFR superfamily that initiates the extrinsic apoptotic pathway. CS-1008 is a humanised, monoclonal IgG1 agonistic antibody (Ab) to human ...

Keywords:

Pathology
Pharmacodynamics
Colorectal cancer
Internal medicine
Medicine
Oncology
Cancer research
Extrinsic apoptotic pathway
tnfr superfamily
Antibody
TNFRSF10B
Monoclonal
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations